Targeting angiogenesis inhibits tumor infiltration and expression of the pro-invasive protein SPARC.
The solid growth of high-grade glioma appears to be critically dependent on tumor angiogenesis. It remains unknown, however, whether the diffuse infiltration of glioma cells into healthy adjacent tissue is also dependent on the formation of new tumor vessels. Here, we analyze the relationship between tumor angiogenesis and tumor cell infiltration in an experimental glioma model. C6 cells were implanted into the dorsal skinfold chamber of nude mice, and tumor angiogenesis was monitored by intravital fluorescence videomicroscopy. Glioma infiltration was assessed by the extent of tumor cell invasion into the adjacent chamber tissue and by expression of SPARC, a cellular marker of glioma invasiveness. To test the hypothesis that glioma angiogenesis and glioma infiltration are codependent, we assessed tumor infiltration in both the presence and the absence of the angiogenesis inhibitor SU5416. SU5416 is a selective inhibitor of the VEGF/Flk-1 signal-transduction pathway, a critical pathway implicated in angiogenesis. Control tumors demonstrated both high angiogenic activity and tumor cell invasion accompanied by strong expression of SPARC in invading tumor cells at the tumor-host tissue border. SU5416-treated tumors demonstrated reduced vascular density and vascular surface in the tumor periphery accompanied by marked inhibition of glioma invasion and decreased SPARC expression. A direct effect of SU5416 on glioma cell motility and invasiveness was excluded by in vitro migration and invasion assays. These results suggest a crucial role for glioma-induced angiogenesis as a prerequisite for diffuse tumor invasion and a possible therapeutic role for anti-angiogenic compounds as inhibitors of both solid and diffuse infiltrative tumor growth.
Vajkoczy
P
P
Department of Neurosurgery, Klinikum Mannheim, University of Heidelberg, Mannheim, Germany. peter.vajkoczy@nch.ma.uni-heidelberg.de
Menger
M D
MD
Goldbrunner
R
R
Ge
S
S
Fong
T A
TA
Vollmar
B
B
Schilling
L
L
Ullrich
A
A
Hirth
K P
KP
Tonn
J C
JC
Schmiedek
P
P
Rempel
S A
SA
D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000818:Animals; D014408:Biomarkers, Tumor / Q000096:biosynthesis; D002455:Cell Division / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D004121:Dimethyl Sulfoxide / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005910:Glioma / Q000098:blood supply / Q000378:metabolism / Q000473:pathology*; D007150:Immunohistochemistry; D007211:Indoles / Q000494:pharmacology; D008297:Male; D051379:Mice; D008819:Mice, Nude; D008856:Microscopy, Fluorescence; D018715:Microscopy, Video; D009361:Neoplasm Invasiveness; D009368:Neoplasm Transplantation; D009389:Neovascularization, Pathologic; D015676:Osteonectin / Q000096:biosynthesis*; D011758:Pyrroles / Q000494:pharmacology; D051381:Rats; D012997:Solvents / Q000494:pharmacology; D013997:Time Factors; D014407:Tumor Cells, Cultured
D020533:Angiogenesis Inhibitors; D014408:Biomarkers, Tumor; D004791:Enzyme Inhibitors; D007211:Indoles; D015676:Osteonectin; D011758:Pyrroles; D012997:Solvents; C116890:Semaxinib; D004121:Dimethyl Sulfoxide